TL
NKTR icon

Tirschwell & Loewy’s Nektar Therapeutics NKTR Stock Holding History

Tirschwell & Loewy’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-133
Closed -$213K – 80
2018
Q1 		$213K Buy
+133
New +$171K 0.03% 78
2015
Q4 		– Sell
-3,340
Closed -$549K – 84
2015
Q3 		$549K Sell
3,340
-6,940
-68% -$1.23M 0.1% 67
2015
Q2 		$1.93M Sell
10,280
-35,883
-78% -$6.18M 0.33% 48
2015
Q1 		$7.62M Buy
46,163
+120
+0.3% +$24.7K 1.27% 32
2014
Q4 		$10.7M Buy
46,043
+5,814
+14% +$1.24M 1.73% 24
2014
Q3 		$7.28M Buy
40,229
+63
+0.2% +$12.1K 1.22% 32
2014
Q2 		$7.72M Buy
40,166
+905
+2% +$160K 1.25% 30
2014
Q1 		$7.14M Buy
39,261
+887
+2% +$176K 1.23% 29
2013
Q4 		$6.53M Buy
38,374
+1,750
+5% +$282K 1.14% 31
2013
Q3 		$5.74M Buy
36,624
+20
+0.1% +$3.7K 1.11% 32
2013
Q2 		$6.34M Buy
+36,604
New +$5.61M 1.35% 26

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Tirschwell & Loewy's NKTR Position: Q2 2018 in Review

Tirschwell & Loewy sold out of Nektar Therapeutics (NKTR) in Q2 2018, closing a stake of 133 shares — an estimated $213K sold.

Tirschwell & Loewy first reported a position in NKTR in Q2 2013 and held it in 11 quarters. The position peaked at $10.7M in Q4 2014. 378 funds tracked by Wall St. Rank hold NKTR as of Q2 2018.

  • Tirschwell & Loewy reported no remaining Nektar Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Tirschwell & Loewy sold 133 Nektar Therapeutics shares in Q2 2018, an estimated $213K.
  • Tirschwell & Loewy first reported a position in Nektar Therapeutics in Q2 2013 and held it in 11 quarters.
  • Tirschwell & Loewy's Nektar Therapeutics position peaked at $10.7M in Q4 2014.
  • 378 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2018.

Based on Tirschwell & Loewy's 13F filing for Q2 2018, filed 3 Aug 2018.